Completed PHASE1 INTERVENTIONAL 2-arm NCT03706924

Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects

Open-Label, Randomized, Parallel-group, Comparative Study of Pharmacokinetics and Bioequivalence of VM-1500FDC (Viriom Ltd, Russia) and Elpida® (Viriom Ltd, Russia) and Truvada® (Gilead Sciences Ireland UC, UK) When сo-administrated Once Daily Fasting in Healthy Subjects

Sponsor: Viriom

Conditions HIV-1-infection

Interventions Elpida® Truvada® VM-1500FDC

Updated 5 times since 2018 Last updated: Oct 29, 2018 Started: Jun 1, 2018 Primary completion: Oct 12, 2018 Completion: Oct 12, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on HIV-1-infection, this trial is completed. The trial is conducted by Viriom and has accumulated 5 data snapshots since 2018. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Nov 2018 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Viriom

Data source: Viriom

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia
• Reutov, Russia